Nanoform Finland (OHEL:NANOFH) Interest Expense : €0.81 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Nanoform Finland Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Nanoform Finland's interest expense for the three months ended in Mar. 2024 was € -0.85 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was €0.81 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Nanoform Finland's Operating Income for the three months ended in Mar. 2024 was € -6.53 Mil. Nanoform Finland's Interest Expense for the three months ended in Mar. 2024 was € -0.85 Mil. Nanoform Finland did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nanoform Finland Interest Expense Historical Data

The historical data trend for Nanoform Finland's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoform Finland Interest Expense Chart

Nanoform Finland Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.14

-0.23

-0.54

-0.22

-0.01

Nanoform Finland Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.44	-1.49	-0.40	3.56	-0.85

Nanoform Finland Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.81 Mil.

Nanoform Finland (OHEL:NANOFH) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nanoform Finland's Interest Expense for the three months ended in Mar. 2024 was €-0.85 Mil. Its Operating Income for the three months ended in Mar. 2024 was €-6.53 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was €5.02 Mil.

Nanoform Finland's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Nanoform Finland did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Nanoform Finland (OHEL:NANOFH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoform Finland PLC (OHEL:NANOFH) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

NANOFS:Sweden 4YL:Germany

Address

Cultivator II, Viikinkaari 4, Helsinki, FIN, 00790

Website

https://www.nanoform.com

Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications.

Nanoform Finland (OHEL:NANOFH) Headlines

No Headlines